Publication: Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency
dc.contributor.buuauthor | Kılıç, Sara Şebnem | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı | |
dc.contributor.orcid | 0000-0001-8571-2581 | tr_TR |
dc.contributor.researcherid | AAH-1658-2021 | tr_TR |
dc.contributor.scopusid | 34975059200 | tr_TR |
dc.date.accessioned | 2022-03-07T08:54:06Z | |
dc.date.available | 2022-03-07T08:54:06Z | |
dc.date.issued | 2005-06 | |
dc.identifier.citation | Kılıç, S. Ş. (2005). "Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency". Journal of Tropical Pediatrics, 51(3), 194-195. | en_US |
dc.identifier.endpage | 195 | tr_TR |
dc.identifier.issn | 0142-6338 | |
dc.identifier.issue | 3 | tr_TR |
dc.identifier.pubmed | 15855303 | tr_TR |
dc.identifier.scopus | 2-s2.0-23944526940 | tr_TR |
dc.identifier.startpage | 194 | tr_TR |
dc.identifier.uri | https://doi.org/10.1093/tropej/fmi027 | |
dc.identifier.uri | https://academic.oup.com/tropej/article/51/3/194/1646327 | |
dc.identifier.uri | http://hdl.handle.net/11452/24866 | |
dc.identifier.volume | 51 | tr_TR |
dc.identifier.wos | 000229545200014 | |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.journal | Journal of Tropical Pediatrics | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Pediatrics | en_US |
dc.subject | Tropical medicine | en_US |
dc.subject | Rheumatoid-arthritis | en_US |
dc.subject.emtree | Antirheumatic agent | en_US |
dc.subject.emtree | Corticosteroid derivative | en_US |
dc.subject.emtree | Immunoglobulin | en_US |
dc.subject.emtree | Infliximab | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Nonsteroid antiinflammatory agent | en_US |
dc.subject.emtree | Tumor necrosis factor | en_US |
dc.subject.emtree | Tumor necrosis factor alpha | en_US |
dc.subject.emtree | Antirheumatic agent | en_US |
dc.subject.emtree | Infliximab | en_US |
dc.subject.emtree | Monoclonal antibody | en_US |
dc.subject.emtree | Case report | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Common variable immunodeficiency | en_US |
dc.subject.emtree | Demyelination | en_US |
dc.subject.emtree | Disease exacerbation | en_US |
dc.subject.emtree | Drug hypersensitivity | en_US |
dc.subject.emtree | Drug infusion | en_US |
dc.subject.emtree | Drug infusion reaction | en_US |
dc.subject.emtree | Elbow disease | en_US |
dc.subject.emtree | Fever | en_US |
dc.subject.emtree | Fibrosing alveolitis | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Immunological parameters | en_US |
dc.subject.emtree | Infection | en_US |
dc.subject.emtree | Juvenile rheumatoid arthritis | en_US |
dc.subject.emtree | Knee arthritis | en_US |
dc.subject.emtree | Knee pain | en_US |
dc.subject.emtree | Laboratory test | en_US |
dc.subject.emtree | Letter | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Malignant neoplastic disease | en_US |
dc.subject.emtree | Physical examination | en_US |
dc.subject.emtree | School child | en_US |
dc.subject.emtree | Splenomegaly | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Tuberculosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Common variable immunodeficiency | en_US |
dc.subject.emtree | Dose response | en_US |
dc.subject.emtree | Drug administration | en_US |
dc.subject.emtree | Hospitalization | en_US |
dc.subject.emtree | Immunology | en_US |
dc.subject.emtree | Risk assessment | en_US |
dc.subject.mesh | Antibodies, monoclonal | en_US |
dc.subject.mesh | Antirheumatic agents | en_US |
dc.subject.mesh | Arthritis, juvenile rheumatoid | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Common variable immunodeficiency | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Drug administration schedule | en_US |
dc.subject.mesh | Follow-up studies | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Risk assessment | en_US |
dc.subject.mesh | Severity of illness index | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.scopus | Common Variable Immunodeficiency; Immunoglobulin Deficiency; Immunosuppression | en_US |
dc.subject.wos | Pediatrics | en_US |
dc.subject.wos | Tropical medicine | en_US |
dc.title | Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı | tr_TR |